NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

TransMedics Group, Inc. (TMDX) Stock Analysis

TransMedics Group, Inc. (TMDX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TMDX

$72.40

−$2.35 (−3.14%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TMDX with… →

TMDX Key Statistics

As of Oct 21, 2026
Trading
Open
$74.47
Previous Close
$74.75
Day's Range
72.26–76.00
52-Week Range
60.11–156.00
Volume
685.38K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.93
Valuation
Market Cap
$2.51B
P/E Ratio
18.76
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
32.12
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.64
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.76
EPS (ttm)Profit attributable to each share over the last twelve months.
3.86
Financials (FY)
Revenue (FY)
$605.49M+37.13%
Net Income (FY)
$190.29M+436.58%
Profit marginThe share of revenue left as profit after all costs and taxes.
22.69%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.68M
1-Year Return
−39.73%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
834.31K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TMDX closed at $72.40, −39.73% over 1 year.

TransMedics Group, Inc. (TMDX) has a market capitalization of $2.51B.

In fiscal 2025, TMDX reported revenue of $605.49M.

TMDX Stock Return by Calendar Year

TransMedics Group, Inc. (TMDX) return since May 2019: what $10,000 became

1 year
$10,000 $6,027
−39.73%
5 years
$10,000 $25,656
+156.56%
Since May 2019
$10,000 $32,379
+223.79%

If you had invested $10,000 in TransMedics Group, Inc. (TMDX) at the close on May 2, 2019, the earliest close on record here, it would have been worth $32,379 at the close on October 21, 2026: +223.79% in total, +17.03% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−40.48%
2025+95.11%
2024−21.01%
2023+27.88%
2022+222.13%
2021−3.72%
2020+4.68%
2019 (partial year)−14.98%

As of October 21, 2026.

TMDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$605.49M$190.29M31.4%
2024$441.54M$35.46M8.0%
2023$241.62M−$25.03M−10.4%
2022$93.46M−$36.23M−38.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$605.49M$362.81M$108.58M$190.29M31.4%
2024$441.54M$262.08M$37.50M$35.46M8.0%
2023$241.62M$154.09M−$28.73M−$25.03M−10.4%
2022$93.46M$65.27M−$31.44M−$36.23M−38.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TMDX Valuation vs Medical Devices Median

Median of 145 stocks
MetricTMDXMedical Devices medianvs median
P/E18.7627.0831% below
P/S ratio3.762.5348% above
Profit margin22.69%−14.78%37.5 pts above

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

TransMedics Group, Inc. (TMDX) is capitalised at $2.51B on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 898 employees.

The 52-week range on file runs from $60.11 to $156.00. TMDX last closed at $72.40 on October 21, 2026. That is −$2.35 (−3.14%) against the previous close. The latest close sits 20.46% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $605.49M. Against the prior fiscal year total of $441.54M, that is a change of +37.13%. The same year closed with net income of $190.29M. That is +436.58% against the prior fiscal year. The reported profit margin is 22.69%. That is 37.5 percentage points above the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to 3.86.

Across the 4 fiscal years on file, revenue moves from $93.46M in 2022 to $605.49M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 18.76. That is 30.72% below the Medical Devices median of 27.08. The forward P/E on file is 32.12. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.64. Measured against sales, the shares trade at 3.76 times revenue. On price-to-sales that is 48.46% above the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.93. Daily returns over the trailing 7 years annualize to a volatility of 71.56%. Over the trailing twelve months the total return is −39.73%. Measured over 5 years, that is +20.74% a year compounded.

Growth & Income

No dividend is on file for TMDX.

The strongest complete calendar year on file is 2022 at +222.13%; the weakest is 2024 at −21.01%. Of the 6 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is −40.48% year to date.

Peer Comparison

TransMedics Group, Inc. (TMDX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TransMedics Group, Inc. TMDX $2.51B 18.8
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. TransMedics Group, Inc. trades at a P/E of 18.8.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About TransMedics Group, Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Visit website →